Drugs / BMS-986235
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04464577 | Apr → Jun 2021 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04301310 | Mar 2020 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03335553 | Nov 2017 → Jul 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03335553 ↗ |
| Known as | LAR-1219 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4784510 ↗ |
| Action | Activate | “the biased FPR small-molecule agonist” PMID 38879891 ↗ Sep 2024 |
| Modality | Small molecule | “the biased FPR small-molecule agonist” PMID 38879891 ↗ Sep 2024 |
| Route | Oral | “BMS-986235 or Placebo oral dose” NCT03335553 ↗ |